- Home
- AKRO vs RYTM Comparison
AKRO vs RYTM Comparison
Compare AKRO & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKRO
- RYTM
- Stock Information
- Founded
- AKRO 2017
- RYTM 2008
- Country
- AKRO United States
- RYTM United States
- Employees
- AKRO N/A
- RYTM N/A
- Industry
- AKRO Biotechnology: Pharmaceutical Preparations
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- AKRO Health Care
- RYTM Health Care
- Exchange
- AKRO Nasdaq
- RYTM Nasdaq
- Market Cap
- AKRO 3.9B
- RYTM 4.3B
- IPO Year
- AKRO 2019
- RYTM 2017
- Fundamental
- Price
- AKRO $54.20
- RYTM $61.99
- Analyst Decision
- AKRO Strong Buy
- RYTM Strong Buy
- Analyst Count
- AKRO 6
- RYTM 12
- Target Price
- AKRO $82.50
- RYTM $76.75
- AVG Volume (30 Days)
- AKRO 1.8M
- RYTM 525.0K
- Earning Date
- AKRO 08-08-2025
- RYTM 08-05-2025
- Dividend Yield
- AKRO N/A
- RYTM N/A
- EPS Growth
- AKRO N/A
- RYTM N/A
- EPS
- AKRO N/A
- RYTM N/A
- Revenue
- AKRO N/A
- RYTM $136,863,000.00
- Revenue This Year
- AKRO N/A
- RYTM $37.56
- Revenue Next Year
- AKRO N/A
- RYTM $74.99
- P/E Ratio
- AKRO N/A
- RYTM N/A
- Revenue Growth
- AKRO N/A
- RYTM 48.88
- 52 Week Low
- AKRO $21.02
- RYTM $39.46
- 52 Week High
- AKRO $58.40
- RYTM $69.89
- Technical
- Relative Strength Index (RSI)
- AKRO 62.96
- RYTM 47.67
- Support Level
- AKRO $53.61
- RYTM $60.70
- Resistance Level
- AKRO $56.49
- RYTM $62.65
- Average True Range (ATR)
- AKRO 2.40
- RYTM 2.39
- MACD
- AKRO -0.08
- RYTM -0.52
- Stochastic Oscillator
- AKRO 65.93
- RYTM 14.04
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.